Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Debt to Equity (2020)

Vistagen Therapeutics (VTGN) has disclosed Debt to Equity for 3 consecutive years, with $0.02 as the latest value for Q3 2020.

  • Quarterly Debt to Equity changed N/A to $0.02 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $0.02 through Sep 2020, changed N/A year-over-year, with the annual reading at -$0.01 for FY2016, N/A changed from the prior year.
  • Debt to Equity hit $0.02 in Q3 2020 for Vistagen Therapeutics, up from -$0.02 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.02 in Q3 2020 to a low of -$0.02 in Q2 2020.